Today Sandoz announced that the US Supreme Court has denied Sandoz appeal for their Enbrel biosimilar (Erelzi; which is FDA approved) to be marketed in the US. This biosimilar is available out side of the US, but wont be US available till 2029. https://t.co/aABw1dpbMr